GERN logo

GERON CORP

GERNNASDAQ
πŸ† #2675 by market capUS Equity
β€”β€”
Quote unavailable
πŸ””
Track GERN
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$561M
Small Cap
πŸ“ˆRevenue Growth (YoY)
18.6%
Healthy
πŸ“ŠGross Margin
96.7%
High
πŸ’΅FCF Margin
4.6%
Moderate
βš–οΈP/S Ratio
2.7x
Cheap
Otter Score
72
Strong
No chart data available for GERN.

Trading Snapshot

Day Range
β€”
52-Week Range
$0.84 – $2.01
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
642.5M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$184M
Last Q Revenue
$60M
P/E Ratio
β€”
P/S Ratio
2.7x
EPS (TTM)
$-0.07
Dividend Yield
β€”
Dilution (1yr)
+3.3%
GERN logo

GERON CORP

GERN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$184Mβ–² +138.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
97.4%β–Ό βˆ’1.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$54Mβ–Ό βˆ’69.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$111Mβ–Ό βˆ’49.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
667.2Mβ–² +3.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$172Mβ–Ό βˆ’$129M YoY
StockOtter Β· stockotter.space

About GERON CORP

Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
72/100
Analyst data unavailable.

Latest News & Updates

News unavailable.